Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin.

Sheridan, D A; Price, D A; Schmid, M L; Toms, G L; Donaldson, P; Neely, D; Bassendine, M F

Sheridan, D A; Price, D A; Schmid, M L; Toms, G L; Donaldson, P; Neely, D; Bassendine, M F.

Affiliation

Sheridan DA; Liver Research Group, Institute of Cellular Medicine, Newcastle University, Newcastleupon Tyne, UK.

Aliment Pharmacol Ther ; 29(12): 1282-90, 2009 Jun 15.

Article in En | MEDLINE | ID: mdl-19392865

Subject(s)

Antiviral Agents/therapeutic use; Apolipoproteins B/genetics; Cholesterol/genetics; Hepatitis C, Chronic/drug therapy; Interferon-alpha/therapeutic use; Ribavirin/therapeutic use; Adult; Apolipoproteins B/metabolism; Cholesterol/metabolism; Female; Humans; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Retrospective Studies; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Antiviral Agents / Apolipoproteins B / Ribavirin / Cholesterol / Interferon-alpha / Hepatitis C, Chronic Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Aliment Pharmacol Ther Year: 2009 Document type: Article

Fulltext

XML

PubMed Links

Search on Google